Celsion Corporation

Celsion Corporation (NASDAQ: CLSN) is a clinical-stage biotechnology company engaged in developing GEN-1, a DNA-based immunotherapy for the targeted treatment of ovarian cancer, and ThermoDox, a heat-activated liposomal encapsulation of doxorubicin for a variety of cancer indications, are among the company's product pipeline.

Key Highlights

• The company reported licensing revenues to USD 125 thousand in Q3FY21 (ended September 30, 2021).
• CLSN's net loss reduced to USD 5.41 million during Q3FY21 vs. USD 8.07 million in Q3FY20.
• As of September 30, 2021, the company had cash and cash equivalents (including short-term investments) of USD 54.51 million and total debt of USD 5.81 million.
• CLSN's Q3FY21 cash cycle of 52 days is lower than the industry median of 72 days.
• Its ROE was -8.8% in Q3FY21 vs. the industry median of -7.7%.
• On February 28, 2022, CLSN stated that it had received USD 1.4 million in net cash proceeds from the sale of USD 1.5 million in unused New Jersey net operating losses (NOLs).
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bearish indicator.
• The stock is leaning towards the lower end of its 52-week range of USD 4.32 to USD 35.40.
• CLSN's stock price decreased 70.50% and 73.05% in the past six and nine months, respectively.

Technical Price Chart (as of March 03, 2022). Source: REFINITIV, Analysis by Kalkine Group

Conclusion: The company is yet to generate product revenues, considering long-term profitability issues, significant correction in the stock price, technical indicators, and associated risks. We recommend a "Avoid" rating on the stock at the closing price of USD 4.69, down 1.26%, as of March 03, 2022.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.